Lyme disease is a most common vector-borne disease caused by the bacterium called as Borrelia burgdorferi. The disease is transmitted to humans through the bite of infected black-legged tick. These ticks can attach themselves to any human body part and transfer the infection to humans when they are attached for 36 to 48 hours. The early symptoms of the disease include headaches, fever, fatigue, muscle and joint pain, skin rash (erythema migrans), chills, and swollen lymph nodes. As reported by the Centers for Disease Control and Prevention (CDC), 70 to 80% of people infected with Lyme disease are affected by erythema migrans.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/862
The Lyme disease is very common in the U.S., especially in Northeastern, North-central and mid-Atlantic parts. However, Lyme disease can also occur in the parts of Pacific Coast spread by western blacklegged ticks. Hence, these regions are expected to witness robust growth in the Lyme disease treatment market. Lyme disease is commonly treated with antibiotics as they are effective for patient with early stages of the disease helping them recover quickly. Patients with severe symptoms of the Lyme disease for 6 months, can recover with treatment of oral antibiotic drugs in few weeks.
Rise in the number of Lyme disease cases and wider scope for development of ideal antibiotics for treating patients with the disease are the factors expected to propel growth of the global Lyme disease treatment market over the forecast period. For instance, International Lyme and Associated Disease Society (ILADS) recommends customised antibiotic treatment for the patients depending on their response to treatment, as Lyme disease is hard to diagnose which results into persistent infection. However, the treatment of antibiotics cannot reduce the infection of Lyme disease, which in turn gives a wider scope for development of ideal antibiotic treatment of Lyme disease.
Moreover, launch of novel vaccines for Lyme disease is also expected to augment growth of the global Lyme disease treatment market. For instance, in July 2017, Valneva SE, a company focused on developing innovative lifesaving vaccines announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its Lyme disease vaccine candidate VLA15.
Extended use of antibiotics could also kill good bacteria in intestine, which could cause various health issues. This, in turn is expected to hamper growth of the global Lyme disease treatment market.
Among regions, North America is expected to witness significant growth in the global Lyme disease treatment market, owing to growing cases of Lyme disease. For instance, as reported by Centers for Disease Control and Prevention (CDC), from 2005 to 2015, about 28,453 Lyme disease cases were registered with 9 new cases per 1,00,000 individuals in the U.S.
Moreover, Europe is also expected to witness robust growth in the global market of Lyme disease treatment during the forecast period. For instance, in 2014, factsheet published by European Centre for Disease Prevention and Control (ECDC) estimated steady increase in the cases of Lyme disease.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/862
By disease type:
Early Lyme disease (absence of erythema migrans)
neurologic Lyme disease
Post-treatment Lyme Disease Syndrome (PTLDS)
Others (azithromycin, clarithromycin, erythromycin)
Key major players active in the Lyme disease treatment market are Hospira Inc., Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc. Lupin Ltd, Sun Pharmaceuticals Industries Ltd., G&W Laboratories, Inc., and Sandoz AG.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027